$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

$pbio Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222033176 Filed on November 21, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$607.2K	$144.0K	$518.4K
YoY Change	92.63%	-72.21%	-2.9%
Cost Of Revenue	$1.271M	$126.2K	$258.2K
YoY Change	642.23%	-51.12%	4.52%
Gross Profit	-$664.1K	$17.83K	$260.2K
YoY Change	-561.46%	-93.15%	-9.29%
Gross Profit Margin	-109.38%	12.38%	50.2%
Selling, General & Admin	$630.0K	$1.119M	$1.220M
YoY Change	-42.86%	-8.3%	42.18%
% of Gross Profit		6275.28%	468.92%
Research & Development	$252.9K	$262.4K	$282.6K
YoY Change	-3.65%	-7.17%	14.22%
% of Gross Profit		1471.59%	108.62%
Depreciation & Amortization	$51.80K	$5.780K	$27.24K
YoY Change	94.74%	-78.78%	-6.62%
% of Gross Profit		32.42%	10.47%
Operating Expenses	$882.9K	$1.381M	$1.503M
YoY Change	-35.32%	-8.09%	35.92%
Operating Profit	-$1.547M	-$1.363M	-$1.243M
YoY Change	26.68%	9.72%	51.76%
Interest Expense	-$3.978M	$2.034M	-$3.492M
YoY Change	33.56%	-158.25%	69.18%
% of Operating Profit
Other Income/Expense, Net	$8.750K	-$3.099M	$60.63K
YoY Change	-107.34%	-5211.13%
Pretax Income	-$4.458M	-$4.462M	-$4.951M
YoY Change	14.92%	-9.87%	51.01%
Income Tax
% Of Pretax Income
Net Earnings	-$4.890M	-$4.462M	-$4.951M
YoY Change	26.05%	-9.87%	51.01%
Net Earnings / Revenue	-805.4%	-3098.09%	-955.13%
Basic Earnings Per Share		-$0.44	-$0.82
Diluted Earnings Per Share	-$0.38	-$400.9K	-$654.8K
COMMON SHARES
Basic Shares Outstanding	11.07M shares	9.074M shares	7.562M shares
Diluted Shares Outstanding		11.13M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.870K	$230.9K	$663.7K
YoY Change	-97.08%	-65.21%	600.42%
Cash & Equivalents	$3.865K	$230.9K	$663.7K
Short-Term Investments
Other Short-Term Assets	$257.5K	$218.5K	$621.0K
YoY Change	-39.06%	-64.82%	288.73%
Inventory	$686.4K	$1.387M	$796.4K
Prepaid Expenses
Receivables	$295.4K	$166.3K	$538.6K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.243M	$2.002M	$2.620M
YoY Change	-33.06%	-23.57%	37.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$103.4K	$111.9K	$175.6K
YoY Change	-10.79%	-36.3%	342.53%
Goodwill
YoY Change
Intangibles	$317.3K	$360.6K
YoY Change	-21.43%
Long-Term Investments	$63.64K	$51.93K	$112.6K
YoY Change	6.11%	-53.86%	-77.64%
Other Assets
YoY Change
Total Long-Term Assets	$766.4K	$838.0K	$713.7K
YoY Change	-21.41%	17.41%	-32.36%
TOTAL ASSETS
Total Short-Term Assets	$1.243M	$2.002M	$2.620M
Total Long-Term Assets	$766.4K	$838.0K	$713.7K
Total Assets	$2.010M	$2.840M	$3.333M
YoY Change	-29.05%	-14.8%	12.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$637.2K	$608.1K	$418.0K
YoY Change	20.71%	45.46%	-40.82%
Accrued Expenses	$2.807M	$2.800M	$2.235M
YoY Change	27.23%	25.23%	-72.4%
Deferred Revenue
YoY Change
Short-Term Debt	$20.10M	$18.83M	$12.87M
YoY Change	42.57%	46.32%	59.14%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.40M	$32.29M	$22.67M
YoY Change	39.71%	42.42%	33.85%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K	$527.0K
YoY Change	0.0%	-71.54%	0.0%
Other Long-Term Liabilities	$141.8K	$171.9K	$110.6K
YoY Change	-46.74%	55.4%	326.16%
Total Long-Term Liabilities	$291.8K	$321.9K	$637.7K
YoY Change	-29.89%	-49.52%	15.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.40M	$32.29M	$22.67M
Total Long-Term Liabilities	$291.8K	$321.9K	$637.7K
Total Liabilities	$34.70M	$32.62M	$23.31M
YoY Change	38.55%	39.91%	33.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$133.8M	-$128.9M
YoY Change	13.15%
Common Stock	$136.8K	$122.2K
YoY Change	50.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$32.69M	-$29.78M	-$19.98M
YoY Change
Total Liabilities & Shareholders Equity	$2.010M	$2.840M	$3.333M
YoY Change	-29.05%	-14.8%	12.71%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$4.890M	-$4.462M	-$4.951M
YoY Change	26.05%	-9.87%	51.01%
Depreciation, Depletion And Amortization	$51.80K	$5.780K	$27.24K
YoY Change	94.74%	-78.78%	-6.62%
Cash From Operating Activities	-$1.427M	-$1.053M	-$1.993M
YoY Change	81.83%	-47.17%	80.17%
INVESTING ACTIVITIES
Capital Expenditures	$10.00	-$15.86K	-$540.00
YoY Change	-100.01%	2837.04%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$10.00	-$15.86K	-$540.00
YoY Change	-99.99%	2837.04%	-99.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$915.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.200M	1.178M	2.611M
YoY Change	222.72%	-54.87%	82.63%
NET CHANGE
Cash From Operating Activities	-1.427M	-1.053M	-1.993M
Cash From Investing Activities	-10.00	-15.86K	-540.0
Cash From Financing Activities	1.200M	1.178M	2.611M
Net Change In Cash	-227.0K	109.3K	617.0K
YoY Change	-57.27%	-82.28%	1057.89%
FREE CASH FLOW
Cash From Operating Activities	-$1.427M	-$1.053M	-$1.993M
Capital Expenditures	$10.00	-$15.86K	-$540.00
Free Cash Flow	-$1.427M	-$1.037M	-$1.993M
YoY Change	114.16%	-47.95%	80.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000830656
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2022Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent		usd
CY2022Q3	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature		usd
	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature		usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
	PBIO	Common Stock Issued For Noncash Warrant Exercise CommonStockIssuedForNoncashWarrantExercise		usd
	PBIO	Noncash Cumulative Effect Period Of Adoption Adjustment NoncashCumulativeEffectPeriodOfAdoptionAdjustment		usd
	PBIO	Discount Due To Beneficial Conversion Feature DiscountDueToBeneficialConversionFeature		usd
	PBIO	Non Cash Deemed Dividendbeneficial Conversion Feature NonCashDeemedDividendbeneficialConversionFeature		usd
	PBIO	Conversion Of Accrued Liabilities And Debt For Preferred Stock ConversionOfAccruedLiabilitiesAndDebtForPreferredStock		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2022Q2	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2021Q3	PBIO	Issuance Of Common Stock For Noncash Warrant Exercise IssuanceOfCommonStockForNoncashWarrantExercise		usd
CY2022Q3	PBIO	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38185
	dei	Entity Registrant Name EntityRegistrantName	PRESSURE BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MA
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-2652826
	dei	Entity Address Address Line1 EntityAddressAddressLine1	14 Norfolk Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South Easton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02375
	dei	City Area Code CityAreaCode	(508)
	dei	Local Phone Number LocalPhoneNumber	230-1828
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11068187	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230880	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132311	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	166314	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	154746	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	342496	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	342496	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1386527	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1147554	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	218476	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	422617	usd
CY2022Q3	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	9929179	usd
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	7757217	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	127091	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37124	usd
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	16708661	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	12839813	usd
CY2022Q3	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	0	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	2002197	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1857228	usd
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	51929	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	59976	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	111884	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	115846	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	313564	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	395565	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	360577	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	403846	usd
CY2022Q3	us-gaap	Assets Assets	2840151	usd
CY2021Q4	us-gaap	Assets Assets	2832461	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	608054	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	527924	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	221938	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	117680	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2435910	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1955672	usd
CY2021Q4	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	0	usd
CY2022Q3	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1555775	usd
CY2021Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1256840	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	565501	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	141649	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	132996	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	32293758	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24625266	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	171915	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262569	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3587	usd
CY2022Q3	us-gaap	Liabilities Liabilities	32615673	usd
CY2021Q4	us-gaap	Liabilities Liabilities	25041422	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	1098	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	1099	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12220611	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12220611	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9120526	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9120526	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	122207	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	91206	usd
CY2022Q3	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31995762	usd
CY2021Q4	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31715154	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	67041489	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64261048	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128936078	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118277468	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-29775522	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2840151	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2832461	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144032	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	518365	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122169	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1687166	usd
CY2022Q3	us-gaap	Revenues Revenues	144032	usd
CY2021Q3	us-gaap	Revenues Revenues	518365	usd
	us-gaap	Revenues Revenues	1122169	usd
	us-gaap	Revenues Revenues	1687166	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	126203	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	258170	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	742707	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	771105	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	262370	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	282622	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	716685	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	839072	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	226526	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	66068	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	422422	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	252209	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	892293	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1154063	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2591644	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2788779	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	1507392	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	1760923	usd
	us-gaap	Costs And Expenses CostsAndExpenses	4473458	usd
	us-gaap	Costs And Expenses CostsAndExpenses	4651165	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1363360	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1242558	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3351289	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2963999	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	2034021	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	3330101	usd
	us-gaap	Interest Expense InterestExpense	6448771	usd
	us-gaap	Interest Expense InterestExpense	11524306	usd
CY2022Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-8675	usd
CY2021Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-162071	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-8047	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-404451	usd
CY2022Q3	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-1054122	usd
CY2021Q3	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-277010	usd
	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-1809249	usd
	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-1500395	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2059	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	60627	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-904	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	119280	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3098877	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3708555	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8266971	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13309872	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4462237	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4951113	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11618260	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16273871	usd
CY2021Q3	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature	815914	usd
	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature	873798	usd
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	431709	usd
CY2021Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	432149	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1295566	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1239535	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4893946	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6199176	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12913826	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18387204	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.02
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11131742	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7561728	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10429817	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6083017	shares
	us-gaap	Net Income Loss NetIncomeLoss	-11618260	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16273871	usd
	PBIO	Gain On Loan Forgiveness GainOnLoanForgiveness	10000	usd
	PBIO	Gain On Loan Forgiveness GainOnLoanForgiveness	367039	usd
	PBIO	Noncash Lease Expense Income NoncashLeaseExpenseIncome	82001	usd
	PBIO	Noncash Lease Expense Income NoncashLeaseExpenseIncome	48158	usd
	PBIO	Common Stock And Warrants Issued For Interest And Extension Fees CommonStockAndWarrantsIssuedForInterestAndExtensionFees	2196278	usd
	PBIO	Common Stock And Warrants Issued For Interest And Extension Fees CommonStockAndWarrantsIssuedForInterestAndExtensionFees	6208696	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	67985	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	83531	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1777863	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-5308424	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1809249	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-23004	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	128984	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	219943	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	-8047	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	-404451	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	367370	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	579512	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11568	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	407404	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	238973	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	203651	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-204141	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	306024	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	80130	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-336675	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	104258	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	39801	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-82001	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-48158	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2083239	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	943400	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3051257	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4083902	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20754	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4503	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20754	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4503	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	1015000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17443	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14773	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3428249	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5054500	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1815000	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1610688	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	762500	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	194600	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1086946	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1608295	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	259600	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	256600	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1506066	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1291150	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3170580	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4733516	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	98569	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	645111	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132311	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18540	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	230880	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	663651	usd
	us-gaap	Interest Paid Net InterestPaidNet	938451	usd
	us-gaap	Interest Paid Net InterestPaidNet	802084	usd
	PBIO	Common Stock Issued For Noncash Warrant Exercise CommonStockIssuedForNoncashWarrantExercise	363	usd
	PBIO	Noncash Cumulative Effect Period Of Adoption Adjustment NoncashCumulativeEffectPeriodOfAdoptionAdjustment	473027	usd
	us-gaap	Stock Issued1 StockIssued1	512593	usd
	us-gaap	Stock Issued1 StockIssued1	551198	usd
	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	93576	usd
	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	1403546	usd
	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	306333	usd
	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	114298	usd
	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	1295566	usd
	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	1239535	usd
	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	350500	usd
	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	2589990	usd
	PBIO	Discount Due To Beneficial Conversion Feature DiscountDueToBeneficialConversionFeature	1231528	usd
	PBIO	Non Cash Deemed Dividendbeneficial Conversion Feature NonCashDeemedDividendbeneficialConversionFeature	873798	usd
	PBIO	Conversion Of Accrued Liabilities And Debt For Preferred Stock ConversionOfAccruedLiabilitiesAndDebtForPreferredStock	500250	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	44	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022Q1	PBIO	Cumulative Effect Period Of Adoption Adjustment CumulativeEffectPeriodOfAdoptionAdjustment	-473027	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64483	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	432149	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	77700	usd
CY2022Q1	PBIO	Issuance Of Common Stock Warrants For Services IssuanceOfCommonStockWarrantsForServices	39761	usd
CY2022Q1	PBIO	Warrants Issued For Debt Extension WarrantsIssuedForDebtExtension	132537	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	472900	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	350500	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	64256	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1173458	usd
CY2022Q1	PBIO	Stock Issued With Debt StockIssuedWithDebt	142480	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	87436	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4239685	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-24748311	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32074	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17443	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	431708	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	67800	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	191303	usd
CY2022Q2	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	151021	usd
CY2022Q2	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	388515	usd
CY2022Q2	PBIO	Stock Issued With Debt StockIssuedWithDebt	35848	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2916338	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-27212353	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32427	usd
CY2022Q3	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	634305	usd
CY2022Q3	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	91056	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	167375	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	431709	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1050475	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	14734	usd
CY2022Q3	PBIO	Stock Issued With Debt StockIssuedWithDebt	334265	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	6140	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4462237	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-29775522	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-16917592	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	61237	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14773	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	403215	usd
CY2021Q1	PBIO	Issuance Of Common Stock Warrants For Interest Paidinkind IssuanceOfCommonStockWarrantsForInterestPaidinkind	600298	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	238512	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	53777	usd
CY2021Q1	PBIO	Preferred Stock Offering PreferredStockOffering	100000	usd
CY2021Q1	PBIO	Beneficial Conversion Option On Convertible Preferred Stock BeneficialConversionOptionOnConvertiblePreferredStock	57884	usd
CY2021Q1	PBIO	Deemed Dividend On Convertible Preferred Stock DeemedDividendOnConvertiblePreferredStock	-57884	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	118000	usd
CY2021Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	2021780	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	162654	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-6577587	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-20527363	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63458	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	404171	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	513070	usd
CY2021Q2	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1432671	usd
CY2021Q2	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	114298	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	231250	usd
CY2021Q2	PBIO	Stock Issued With Debt StockIssuedWithDebt	112877	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	906188	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4745171	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-22302893	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	95248	usd
CY2021Q3	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	2153947	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	341000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	432149	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2240740	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	334704	usd
CY2021Q3	PBIO	Preferred Stock Issued During Period Value Issued For Debt Settlement PreferredStockIssuedDuringPeriodValueIssuedForDebtSettlement	523254	usd
CY2021Q3	PBIO	Preferred Stock Offering PreferredStockOffering	915000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	664681	usd
CY2021Q3	PBIO	Beneficial Conversion Option On Convertible Preferred Stock BeneficialConversionOptionOnConvertiblePreferredStock	815914	usd
CY2021Q3	PBIO	Deemed Dividend On Convertible Preferred Stock DeemedDividendOnConvertiblePreferredStock	-815914	usd
CY2021Q3	PBIO	Stock Issued With Debt StockIssuedWithDebt	438321	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4951113	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-19979260	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zY6oIQzeu9Yg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	518000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1687000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	518000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1687000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	518000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1122000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1687000	usd
CY2022Q3	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	166000	usd
CY2021Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	155000	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	127000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	41000	usd
CY2022Q3	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	127000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zcqQMbcHTH1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentrations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueConcentrationOfRiskTextBlock_zuS2EDBjVek1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zgcHgcUHBKl4" style="display: none">Schedule of Customer Concentration Risk Percentage</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Three Months Ended</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Nine Months Ended</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Top Five Customers</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVcgHWIpVFX2" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Concentration credit risk percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmUtoELY2Abd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Concentration credit risk percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2IBd5iLY8Z4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5ku4bu4yWTb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal Agencies</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkB2JiSVHZHh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Concentration credit risk percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGnqUPxnztV" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Concentration credit risk percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbpXsnVGDPaf" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zichDiPvDTH3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30,<br/> 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,<br/> 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Top Five Customers</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXKkL66DcuJc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Concentration credit risk percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMVQGtnhlpS4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Concentration credit risk percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal Agencies</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2aPjP1LtdLl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Concentration credit risk percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zShefd21Dbh1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Concentration credit risk percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A8_zdDG5Wyn07r3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4893946	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6199176	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12913826	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18387204	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11131742	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7561728	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10429817	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6083017	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.02
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33217416	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32087170	shares
CY2022Q3	PBIO	Forfeiture Rate ForfeitureRate	0.05	pure
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	32427	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	95248	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	128984	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	219943	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	32427	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	95248	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	128984	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	219943	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	51929	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	59976	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	57971	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	149299	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	64393	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	66969	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	51778	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	390410	usd
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.5
	PBIO	Debt Instrument Discount Percentage Of Stock Price DebtInstrumentDiscountPercentageOfStockPrice	0.25	pure
	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.35	pure
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
	PBIO	Debt Instrument Discount Percentage Of Stock Price DebtInstrumentDiscountPercentageOfStockPrice	0.25	pure
	PBIO	Debt Instrument Discount Percentage Of Stock Price DebtInstrumentDiscountPercentageOfStockPrice	0.25	pure
	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	10	pure
	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	891307	usd
CY2021	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	861500	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
	PBIO	Debt Instrument Purchase Price DebtInstrumentPurchasePrice	1385000	usd
	PBIO	Debt Instrument Purchased Amount DebtInstrumentPurchasedAmount	1854890	usd
CY2022Q3	PBIO	Debt Instrument Outstanding Balance DebtInstrumentOutstandingBalance	664468	usd
CY2021	PBIO	Debt Instrument Purchase Price DebtInstrumentPurchasePrice	525000	usd
CY2021	PBIO	Debt Instrument Purchased Amount DebtInstrumentPurchasedAmount	686250	usd
CY2021Q4	PBIO	Debt Instrument Outstanding Balance DebtInstrumentOutstandingBalance	398910	usd
CY2021Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	8500	usd
CY2022Q3	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	1098	usd
CY2021Q4	us-gaap	Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue	1099	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17540209	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17308567	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	277500	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25279	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	190840	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17601590	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17533679	shares
	PBIO	Warrants And Rights Acquisition WarrantsAndRightsAcquisition	200100	shares
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	245635	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-23004	usd

Files In Submission

Name	View Source	Status
0001493152-22-033176-index-headers.html	Edgar Link	pending
0001493152-22-033176-index.html	Edgar Link	pending
0001493152-22-033176.txt	Edgar Link	pending
0001493152-22-033176-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbio-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pbio-20220930_cal.xml	Edgar Link	unprocessable
pbio-20220930_def.xml	Edgar Link	unprocessable
pbio-20220930_pre.xml	Edgar Link	unprocessable
pbio-20220930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

2022 Q4 Form 10-Q Financial Statement

#000149315222033176 Filed on November 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO PRESSURE BIOSCIENCES INC Stock $pbio

2022 Q4 Form 10-Q Financial Statement

#000149315222033176 Filed on November 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio